RWD20 Analysis of US Real World Evidence Data to Assess and Compare the Effectiveness of Two Chemotherapy Regimens: FOLFIRINOX Vs Gemcitabine/Nab-paclitaxel for First Line Metastatic Pancreatic Cancer
Jun 1, 2023, 00:00
10.1016/j.jval.2023.03.2050
https://www.valueinhealthjournal.com/article/S1098-3015(23)02150-2/fulltext
Title :
RWD20 Analysis of US Real World Evidence Data to Assess and Compare the Effectiveness of Two Chemotherapy Regimens: FOLFIRINOX Vs Gemcitabine/Nab-paclitaxel for First Line Metastatic Pancreatic Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)02150-2&doi=10.1016/j.jval.2023.03.2050
First page :
Section Title :
Open access? :
No
Section Order :
11369